Imexpharm Corporation (HOSE:IMP)

Market Cap	7.72T
Revenue (ttm)	2.45T
Net Income (ttm)	333.14B
Shares Out	154.01M
EPS (ttm)	2,163.10
PE Ratio	23.16
Forward PE	23.17
Dividend	500.00 (1.03%)
Ex-Dividend Date	Jun 9, 2025

Volume	54,549
Average Volume	42,682
Open	48,500
Previous Close	48,550
Day's Range	48,000 - 50,100
52-Week Range	36,100 - 56,500
Beta	0.72
RSI	45.96
Earnings Date	Jan 16, 2026

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.